New eczema drug SYX-5219 enters first human safety trials
Symptom relief
Recruiting now
This early-stage study tests a new drug called SYX-5219 in healthy people and those with moderate to severe atopic dermatitis (eczema). The main goal is to check safety and how the body processes the drug. Up to 149 participants will receive either the drug or a placebo over seve…
Phase: PHASE1 • Sponsor: Sitryx Therapeutics Ltd • Aim: Symptom relief
Last updated May 17, 2026 06:50 UTC